Histone deacetylase: a potential therapeutic target for fibrotic disorders.
Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone acetyltransferases on chromatin remodeling and play essential roles in regulating gene transcription. In the past several years, the role of HDACs in cancer initiation and progression, as well as the therapeutic effects of HDAC inhibitors in various types of cancer, has been well studied. Recent studies indicated that HDAC activity is also associated with the development and progression of some chronic diseases characterized by fibrosis, including chronic kidney disease, cardiac hypertrophy, and idiopathic pulmonary fibrosis. Here, we review what is known about HDACs in the progression of tissue fibrosis and the potential applications of HDAC inhibitors in the treatment of disorders associated with fibroblast activation and proliferation.
Pang
Maoyin
M
Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Middle House 301, 593 Eddy Street, Providence, RI 02903, USA.
Zhuang
Shougang
S
D006332:Cardiomegaly / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D005355:Fibrosis; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology
D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases